Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Moore

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Dermatology and Therapy|May 16, 2026
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb TrialNada Elbuluk, April W Armstrong, Ronald Vender, et al.
Annals of Surgical Oncology|September 30, 2006
Ultrasound-guided fine-needle aspiration of clinically negative lymph nodes versus sentinel node mapping in patients at high risk for axillary metastasisJoseph T Davis, Yolanda M Brill, Sam Simmons, et al.
The Journal of Pediatrics|September 28, 2013
Early adversity, socioemotional development, and stress in urban 1-year-old childrenFrederick B Palmer, Kanwaljeet J S Anand, J Carolyn Graff, et al.
American Journal of Clinical Dermatology|January 14, 2026
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)Christopher G Bunick, Nina Magnolo, Angela Moore, et al.
Dermatology and Therapy|October 15, 2023
Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled StudyStephen Schleicher, Angela Moore, Elyse Rafal, et al.
Dermatology and Therapy|January 12, 2024
Correction: Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled StudyStephen Schleicher, Angela Moore, Elyse Rafal, et al.
American Journal of Clinical Dermatology|July 15, 2025
Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable StudyAndrew Alexis, Ali Moiin, Jill Waibel, et al.
Clinical and Experimental Dermatology|May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trialStephen Tyring, Angela Moore, Akimchi Morita, et al.
American Journal of Clinical Dermatology|May 17, 2023
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical TrialsLinda Stein Gold, Diamant Thaçi, Jacob P Thyssen, et al.
Dermatology and Therapy|February 21, 2025
Recommendations to Improve Outcomes in Acne and Acne Sequelae: A Focus on Trifarotene and Other RetinoidsNaiem Issa, Andrew Alexis, Hilary Baldwin, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Dermatology and Therapy|May 16, 2026
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb TrialNada Elbuluk, April W Armstrong, Ronald Vender, et al.
Annals of Surgical Oncology|September 30, 2006
Ultrasound-guided fine-needle aspiration of clinically negative lymph nodes versus sentinel node mapping in patients at high risk for axillary metastasisJoseph T Davis, Yolanda M Brill, Sam Simmons, et al.
The Journal of Pediatrics|September 28, 2013
Early adversity, socioemotional development, and stress in urban 1-year-old childrenFrederick B Palmer, Kanwaljeet J S Anand, J Carolyn Graff, et al.
American Journal of Clinical Dermatology|January 14, 2026
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)Christopher G Bunick, Nina Magnolo, Angela Moore, et al.
Dermatology and Therapy|October 15, 2023
Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled StudyStephen Schleicher, Angela Moore, Elyse Rafal, et al.
Dermatology and Therapy|January 12, 2024
Correction: Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled StudyStephen Schleicher, Angela Moore, Elyse Rafal, et al.
American Journal of Clinical Dermatology|July 15, 2025
Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable StudyAndrew Alexis, Ali Moiin, Jill Waibel, et al.
Clinical and Experimental Dermatology|May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trialStephen Tyring, Angela Moore, Akimchi Morita, et al.
American Journal of Clinical Dermatology|May 17, 2023
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical TrialsLinda Stein Gold, Diamant Thaçi, Jacob P Thyssen, et al.
Dermatology and Therapy|February 21, 2025
Recommendations to Improve Outcomes in Acne and Acne Sequelae: A Focus on Trifarotene and Other RetinoidsNaiem Issa, Andrew Alexis, Hilary Baldwin, et al.
Pageof 6